Taiwan firms aim to expand hep B treatment with generic Baraclude
This article was originally published in Scrip
Two Taiwanese firms are planning to launch a generic version of Bristol-Myers Squibb's hepatitis B drug Baraclude (entecavir) in their home market by the end of the year, in a move they expect to improve low treatment rates for the disease.
You may also be interested in...
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.